Novel Antibiotic Agents to Combat Resistant Bacteria
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacteria. Omnix is developing a novel IV medication for the treatment of life-threatening hospital-acquired infections. Omnix technology employs unique and fast-acting peptides exerting a bactericidal effect, making it very difficult for bacteria to develop tolerance or resistance. Omnix Medical's agents have been granted QIDP designation by the FDA and are eligible for Breakthrough-Therapy status. The company's strategy to combat bacteria may serve to circumvent the development of antimicrobial resistance and may offer a treatment where therapeutic options are scarce.